Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

377P - Intraindividual tumor heterogeneity of mismatch repair status in metastatic colorectal cancer

Date

10 Sep 2022

Session

Poster session 08

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Gang Liu

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

G. Liu, Q. Huang, Q. Zhang, K. Li, S. Zhang, T. Liu

Author affiliations

  • Department Of General Surgery, Tianjin Medical University General Hospital, 300052 - Tianjin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 377P

Background

Tumor DNA mismatch repair (MMR) deficiency testing has become an indispensable test in metastatic colorectal cancer (mCRC) due to the high efficacy of immunotherapy in patients with deficient MMR (dMMR) status. However, a significant portion of dMMR CRC tumors exhibit primary or acquired resistance. Heterogeneous MMR status may associate with refractoriness to immunotherapy. We aimed to study the concordance in MMR status between primary and paired metastasis in mCRC.

Methods

Our study included 84 mCRC patients with both primary and matched metastatic sites. Immunohistochemistry was used to determine the MMR patterns of primary lesions and metastases. A pooled analysis including 913 cases was used to determine the frequency and organ-specific heterogeneity of MMR status. The relationship between MMR phenotype heterogeneity and clinical outcomes was investigated.

Results

10 (11.9%) of the patients had MMR status heterogeneity between primary and metastatic tumours. Prevalence of heterogeneous MMR patterns is significantly higher in patients with dMMR primary tumors than patients with proficient MMR (pMMR) primary tumors and which was also verified in the pooled analysis (P<0.001). MMR status discordance between primary and metastatic tumours was more common in patients with peritoneal metastases (10.67%). For the patients with dMMR primary tumours, the discrepancy regarding MMR status was observed in patients with liver, lung, ovary, peritoneum, and distant lymph node metastasis. For the patients with pMMR primary tumours, the discrepancy was more likely to be limited to liver ((26/440) or peritoneal (7/112) metastasis (P=0.02).The patients with isolated heterogeneous expression of MSH6 and PMS2, as well as paired heterogeneous expression of MSH2/MSH6 and MLH1/PMS2, were relatively higher. Patients with MMR status heterogeneity or not had comparable OS (P=0.452).

Conclusions

Heterogeneous MMR patterns exist in a subset of mCRC patients, especially in patients with dMMR primary tumors. Testing the metastatic site might be valuable in cases of peritoneal metastasis as the discordance of MMR status potentially could affect immune surveillance and immunotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.